These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7974364)

  • 21. Immune tolerance induction in hemophilia A: a review.
    Mariani G; Siragusa S; Kroner BL
    Semin Thromb Hemost; 2003 Feb; 29(1):69-76. PubMed ID: 12640568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital].
    Diniz MJ; Dias Francisco F; Tavares ML; Leal I
    Acta Med Port; 1992 Apr; 5(4):178-80. PubMed ID: 1605065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.
    DiMichele DM; Kroner BL;
    Thromb Haemost; 2002 Jan; 87(1):52-7. PubMed ID: 11848456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab in the treatment of high responding inhibitors in severe haemophilia A.
    Moschovi M; Aronis S; Trimis G; Platokouki H; Salavoura K; Tzortzatou-Stathopoulou F
    Haemophilia; 2006 Jan; 12(1):95-9. PubMed ID: 16409183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry.
    Haya S; López MF; Aznar JA; Batlle J;
    Haemophilia; 2001 Mar; 7(2):154-9. PubMed ID: 11260274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab for adolescents with haemophilia and high titre inhibitors.
    Fox RA; Neufeld EJ; Bennett CM
    Haemophilia; 2006 May; 12(3):218-22. PubMed ID: 16643204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioactive synoviorthesis in patients with hemophilia with factor inhibitor.
    Löfqvist T; Petersson C; Nilsson IM
    Clin Orthop Relat Res; 1997 Oct; (343):37-41. PubMed ID: 9345203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols.
    Mariani G; Scheibel E; Nogao T; Kasper CK; Ewing NP; Mauser-Bunschoten E; Ghirardini A; Bellocco R; Brackman HH
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):62-4. PubMed ID: 7939781
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ablation of hemophilic FVIII inhibitors with FVIII priming, cyclophosphamide immune suppression, and rapid tapering of FVIII immune tolerance.
    Kobrinsky NL; Sjolander DE; Moser DK; Stegman DA
    Am J Hematol; 2004 Jun; 76(2):180-4. PubMed ID: 15164387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The German Registry of immune tolerance treatment in hemophilia--1999 update.
    Lenk H;
    Haematologica; 2000 Oct; 85(10 Suppl):45-7. PubMed ID: 11187870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction.
    Caram C; de Souza RG; de Sousa JC; Araújo Pereira T; do Amaral Cerqueira AM; van der Bom JG; Rezende SM
    Thromb Haemost; 2011 Jan; 105(1):59-65. PubMed ID: 21057702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated.
    Scheibel E; Ingerslev J; Dalsgaard-Nielsen J; Stenbjerg S; Knudsen JB
    Thromb Haemost; 1987 Dec; 58(4):1049-52. PubMed ID: 3127918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
    van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
    Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.